INS and type 2 diabetes mellitus: In several large trials of up to 26 weeks' duration, alogliptin in monotherapy or in combination with other oral antihyperglycaemic agents (metformin, glibenclamide, or pioglitazone) or insulin therapy has improved glycaemic control in adult patients with inadequately controlled T2DM [201, 202].